Improving T-Cell Therapy for Sarcoma
Gene-Product Auto-Targeting to Tumor Vessels
This project aims to make T-cell therapies, like CAR-T, safer and more effective for patients with sarcoma by specifically targeting treatments to tumor cells.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Tx Md Anderson Can Ctr NIH-funded |
| Lab location | 1 site (Houston, United States) |
| Project ID | NIH-11076311 on NIH RePORTER |
What this research studies
For patients with recurrent or metastatic sarcoma, current treatments are often limited, and new options are urgently needed. This project focuses on enhancing immune cell therapies, such as CAR-T cells, which use a patient's own immune cells to fight cancer. Researchers are working to improve these therapies by adding a special gene product called IL12, which can boost the immune response against tumors. A key challenge with these powerful treatments is managing side effects, so this project is developing a new, targeted version of IL12 designed to specifically attack tumor cells while minimizing harm to healthy tissues. The goal is to create a more powerful and safer treatment option for sarcoma patients.
Who could benefit from this research
Good fit: Patients with recurrent or metastatic soft tissue sarcoma or osteosarcoma, especially those whose tumors have spread to the lungs, might be ideal candidates for future therapies based on this research.
Not a fit: Patients with cancer types other than sarcoma, or those who are not candidates for T-cell based immunotherapies, may not directly benefit from this specific approach.
Why it matters
Potential benefit: If successful, this work could lead to more effective and less toxic immune therapies for patients battling aggressive forms of sarcoma.
How similar studies have performed: While T-cell therapies and IL12 have shown promise in other tumor types, this specific method of targeting IL12 to tumor vessels to reduce side effects is a novel approach.
Where this research is happening
Houston, United States
- University of Tx Md Anderson Can Ctr — Houston, United States (Active)
Researchers
- Principal investigator: Li, Shulin — University of Tx Md Anderson Can Ctr
- Study coordinator: Li, Shulin
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.